Medpace (NASDAQ:MEDP) CEO August Troendle Sells 6,047 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 6,047 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $591.00, for a total transaction of $3,573,777.00. Following the transaction, the chief executive officer owned 893,368 shares in the company, valued at $527,980,488. The trade was a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Medpace Price Performance

NASDAQ MEDP traded up $4.42 on Tuesday, reaching $590.18. 219,107 shares of the company’s stock traded hands, compared to its average volume of 415,017. The stock has a market cap of $16.62 billion, a PE ratio of 41.27, a P/E/G ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $625.00. The stock has a 50-day simple moving average of $541.26 and a 200 day simple moving average of $426.46.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. During the same period in the previous year, the business posted $3.01 EPS. The business’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MEDP. Robert W. Baird set a $613.00 price objective on Medpace in a research report on Friday, October 24th. BMO Capital Markets assumed coverage on shares of Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target for the company. Mizuho boosted their price objective on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. UBS Group downgraded shares of Medpace from a “neutral” rating to a “sell” rating and upped their price objective for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. Finally, Truist Financial set a $555.00 target price on Medpace in a report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $487.18.

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently bought and sold shares of the business. Quent Capital LLC purchased a new stake in Medpace during the 3rd quarter valued at approximately $25,000. Optiver Holding B.V. purchased a new position in Medpace during the third quarter valued at $27,000. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Brooklyn Investment Group lifted its stake in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after purchasing an additional 71 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Medpace during the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.